Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can school lessons boost teen vaccine uptake?

NCT ID NCT07824076

Prevention Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers compare one French middle school that used the e-Bug educational programme with other schools in the region to see whether classroom lessons about vaccination relate to higher HPV and meningococcal ACWY vaccine coverage. The study uses only aggregated, anonymised vaccination data that health authorities routinely collect, so no students or parents are enrolled or individually tracked. It asks whether teaching children about diseases and vaccines before the national school vaccination campaign may be associated with more parents giving consent.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
e-Bug school-based educational programme about vaccination
What this could lead to
If the pattern holds, schools could adopt classroom lessons to raise parental consent and teen vaccination rates against HPV and meningococcal disease.
What could go wrong
This is a small observational comparison of one school against regional averages, so it cannot prove the lessons caused any difference. Many other factors shape whether parents consent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

53,608 people

The number who actually took part.

Started

May 2026

Finished

Sep 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Aggregated data from 5th-grade students enrolled in one pilot middle school using the e-Bug programme, compared with aggregated data from all other middle schools in the Alpes-Maritimes department and PACA region. No individual-level data were accessed.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * No individual participants are enrolled. The study uses only aggregated, anonymised vaccination data routinely collected by ARS PACA. Exclusion Criteria: * Not applicable. No individual-level inclusion or exclusion criteria are defined, as no participants are enrolled.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV coverage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious meningitis human papilloma virus infection prevention target meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV coverage Meningitidis infections Meningococcal acwy vaccines Vaccination coverage

Contacts and locations

Locations

  • CHU de Nice

    Nice, Alpes Maritimes, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.